Der Übernahmekick - 500 Beiträge pro Seite

[URANI]

Auszug aus dem Aktionär Nr. 12 (14.03-20.03.2007)

Glaubt man den Spekulationen, die derzeit hinter vorgehaltender Hand im US-Markt kursieren, könnten sich die Aktionäre der US-Biotech-Firma BIOENVISION demnächst sogar über eine hohe Rendite freuen. Denn dem Vernehmen nach ist ein größerer Konkurrent an einer Übernahme von BIOENVISION interessiert und dabei bereit, bis zu 15 Dollar je Aktie zu zahlen.


Ein möglicher Aufkäufer ist das Biotech-Schwergewicht Genzyme. Die Gründe liegen auf der Hand: Genzyme hält die Rechte am von Bioenvision entwickelten Leukämiemittel "Evoltra" und muss vereinbarungsgemäß Umsatz und Gewinnbeteilung an Bioenvision abführen. Diese Zahlungen fallen bis jezut noch moderat aus, denn aktuell ist Evoltra lediglich für die Behandlung von Kindern und Erwachsenden bis 21 Jahre zugelassen. Doch aktuell laufen in Europa Studien, die belegen soll dass sich das Präperat auch zur Therapie von erwachsenden eignet. Damit würde sich das Marktpotenzial erhöhen. Die Ergebnisse der Studie werden bis zum ende des Jahres erwartet.

Bioenvision hat 30 Millionen nDollar Cash.



Über Bioenvision

Der Haupttätigkeitsschwerpunkt von Bioenvision liegt auf Erwerb, Entwicklung, Vertrieb und Marketing von Verbindungen und Technologien zur Krebsbehandlung. Bioenvision hat eine breite Pipeline von Produkten zur Krebsbehandlung, darunter: Evoltra(R), Modrenal(R) (für das Bioenvision die amtliche Marktzulassung in Großbritannien zur Behandlung von postmenopausalem Brustkrebs nach Rezidiv nach anfänglicher Hormonbehandlung besitzt) und andere Produkte. Bioenvision entwickelt auch Infektions-hemmende Technologien, darunter die OLIGON(R) Technologie, ein fortschrittliches Biomaterial, das in mehrere von der US-Arzneimittelbehörde zugelassene medizinische Geräte eingebaut wurde, und Suvus(R), einen zur Zeit in der klinischen Entwicklung befindlichen antimikrobiellen Wirkstoff gegen refraktäre chronische Infektion mit Hepatitis C. Nähere Informationen über Bioenvision finden Sie auf unserer Website unter www.bioenvision.com.


WKN: 215162
ISIN: US09059N1000
Kürzel: BIVN
MK: 180 Mio. US-$
Umsatz: 20 Mio. US-$

Risiokofreudige Anleger setzten auf ein baldiges Übernahmeangebot.
Totalverlust ist nicht ausgeschlossen

[URANI]

[URANI]

Management Team

Dr. Christopher B. Wood
Chairman, Chief Executive Officer

Dr. Christopher B. Wood has served as the Chairman and Chief Executive Officer of Bioenvision since January 1999. From January 1997 to December 1998, Dr. Wood was chairman of Eurobiotech, Inc.

He has more than 15 years of experience in the European biotechnology sector and has taken two biotechnology companies from start-up through commercialization. One of these, Medeva PLC., traded on the London Stock Exchange and the New York Stock Exchange, and is now wholly owned by Celltech Group PLC.

Dr. Wood holds an M.D. from the University of Wales School of Medicine and is a Fellow of the Royal College of Surgeons of Edinburgh. From 1994 to 1997, Dr. Wood was employed as a specialist surgeon within the National Health Service in the UK. From 1979 to 1991, Dr. Wood was a specialist surgeon at The Royal Postgraduate Medical School in London.

David P. Luci
Executive Vice President, General Counsel and Corporate Secretary

David P. Luci, C.P.A., Esq. was appointed Executive Vice President, General Counsel and Corporate Secretary in December 2006. Mr. Luci is responsible for the management of business development and certain product development activities and manages the Company’s legal and regulatory matters. Mr. Luci served as the Company’s Chief Financial Officer, General Counsel and Corporate Secretary from July 2002 to December 2006. From September 1994 to July 2002, Mr. Luci served as a corporate associate at Paul, Hastings, Janofsky & Walker LLP. Prior to that, Mr. Luci served as a senior auditor at Ernst & Young LLP (New York office).

Mr. Luci is a certified public accountant. He holds a Bachelor of Science in Business Administration with a concentration in accounting from Bucknell University and a J.D. from Albany Law School of Union University.

Hugh Griffith
Chief Operating Officer

Hugh Griffith has served as Chief Operating Officer of Bioenvision Limited since July 2004 after serving as Commercial Director (Europe) since October 2002.

Mr Griffith served as Executive Commercial Director of QuantaNova Ltd. from January 2002 to September 2002. From October 1995 to December 2001, Mr Griffith held several senior commercial positions at Abbott Laboratories, including Senior Business Unit Manager, Business Development Manager and Area Sales Manager. From April 1992 to October 1995 Mr Griffith served with Parke-Davis, Warner Lambert.

Mr Griffith holds a Masters of Business Administration from Cardiff Business School, University of Wales; a Diploma of Marketing; and a Bachelor of Science with Honours in Biology from the University of Stirling in Scotland.

James S. Scibetta
Chief Financial Officer

Mr. Scibetta joined Bioenvision as its Chief Financial Officer in December 2006. From September 2001 to November 2006, Mr. Scibetta was Executive Vice President & CFO of Merrimack Pharmaceuticals, Inc., a biopharmaceutical company focused on discovery and development of novel therapies for autoimmune disease and cancer, and he was a member of the Board of Directors of Merrimack from April 1998 to March 2004. Mr. Scibetta is a member of the Board of Directors and Audit Committee Chairman of Labopharm Inc. (NasdaqDSS, TSXDS), an international, specialty pharmaceutical company focused on improving existing drugs by incorporating its proprietary, advanced controlled-release technologies. Mr. Scibetta formerly served as a senior investment banker providing capital raising, M&A and strategic advisory services to healthcare companies at Shattuck Hammond Partners, LLC from 1997 to 2001 and PaineWebber Inc. from 1988 to 1997.

Mr. Scibetta holds a B.S. in Physics from Wake Forest University, and an M.B.A. in Finance from the University of Michigan. He completed executive education studies in the Harvard Business School Leadership & Strategy in Pharmaceuticals and Biotechnology program.

Ian Abercrombie
Programme Director

Mr Abercrombie is responsible for the sales of the Bioenvision product portfolio throughout Europe. He is also involved in the development of the Bioenvision pipeline.

Mr Abercrombie joined Bioenvision from his position of European Sales and Marketing Director with Biolitec Pharma. During his spell with Biolitec Pharma he led the successful commercialization of their leading Photosensitizer in oncology.

Before joining the biotech sector Mr Abercrombie enjoyed a successful career in Johnson and Johnson. Rising to senior management within the Ortho-biotech division he recruited and led a high performing Oncology team.

Prior to joining the pharmaceutical industry Ian had spent five years in Public Health, having initially trained as a nurse (RGN) in Glasgow.

Rob Sterling
Vice President, Business Development

Mr. Sterling joined Bioenvision in December 2001. He is responsible for development of Bioenvision's anti-viral, anti-microbial and veterinary businesses.

Mr. Sterling worked for nine years at Hoechst Roussel Vet, where he held various marketing and sales positions and led the Companion Animal Business Unit during his last three years with the Company. Mr. Sterling directed highly successful re-launches of two mature pharmaceuticals, and oversaw the development of various new products.

Mr. Sterling holds a B.S. degree from Penn State University.

Kristen M. Dunker
Vice President, Corporate Compliance and Associate General Counsel

Kristen M. Dunker, Esq. has served as Vice President, Corporate Compliance and Associate General Counsel since June 2004. From September 1999 to June 2004, Ms. Dunker served as a corporate associate at Paul, Hastings, Janofsky & Walker LLP.

Ms. Dunker holds a Bachelor of Science in Business Administration from Bucknell University and a J.D. from the University of Denver College of Law.

MaryJane Rafii, PhD
Vice President of Regulatory Affairs

Dr. MaryJane Rafii joined Bioenvision in October of 2006 as Vice President of Regulatory Affairs. Dr. Rafii came to Bioenvision from the Ludwig Institute for Cancer Research in New York where she was Head of Regulatory Affairs and Pharmacovigilance. She had been with the Institute since April 1999. Dr. Rafii oversaw regulatory affairs at Sankyo USA in New York from 1995 until 1999. She began her regulatory career at Escalon Ophthalmics in 1993.

Dr. Rafii earned her Ph.D. in immunology and biochemistry from the University of Cardiff, Wales, United Kingdom. She received her master's degree in protein modeling from UC San Francisco and a bachelor's degree in molecular biology/marketing and international finance from the University of Southern California.

[URANI]

Evoltra(TM) wurde der Orphan Drug Status verliehen, was eine
10-jährige Vertriebsexklusivität ab Marktzulassung in Europa gewährt.
Bioenvision untersucht derzeit die Wirkung von Evoltra(TM) bei
anderen Leukämiearten und deutete auch auf Aktivitäten bei anderen
Krebsarten hin.

[URANI]

Antwort auf Beitrag Nr.: 28.297.045 von URANI am 14.03.07 20:38:22

Sorry, habe da Datum vergessen: Der Artikel stammt vom Januar 2006

[stock_budgie]

Antwort auf Beitrag Nr.: 28.296.803 von URANI am 14.03.07 20:24:50

15 dollar - warum nicht 30 oder 45

warum kein 8 - wäre doch ein aufschlag von 100%